The standard first-line treatment of castration-resistant prostate cancer (CRPC) is docetaxel-based chemotherapy.
However,CRPC may not respond to docetaxel due to drug resistance or other causes.Several new therapeutic agents have been developed, some of which are approved by FDA or on clinical trials. The mechanisms of action of these agents include stabilizing microtubules,inhibiting hormone synthesis, blocking androgen receptor, bone targeting or immune regulation. In this article we review the novel therapeutic options for CPRC after docetaxel failure.
Written by:
Chen BD, Yu SC, Li GH. Are you the author?
Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Reference: Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 Jan;43(1):115-8.
PubMed Abstract
PMID: 24616470
Article in Chinese.
UroToday.com Prostate Cancer Section
